Literature DB >> 6720271

Laser trabeculoplasty as primary therapy in chronic open angle glaucoma.

A Tuulonen.   

Abstract

Sixty-three phakic eyes of 54 patients with early simple (21 eyes) or capsular (42 eyes) glaucoma treated with laser trabeculoplasty (LTP) as the primary therapy were followed retrospectively 12 to 18 months after LTP. In 59 of 63 eyes followed up for 12 months and 46 of 52 eyes followed up for 18 months the intraocular pressure (IOP) was constantly maintained below 22 mmHg with no medication. After a good initial response for 6 to 12 months, 6 eyes required medical therapy because of uncontrolled pressure or progression in the damage of the optic disc or visual fields. The mean pressure reduction of all eyes 18 months after LTP was 28% in simple and 37% in capsular glaucoma. No severe complications were seen. LTP seems to be an effective and safe procedure as the primary therapy for open angle glaucoma.

Entities:  

Mesh:

Year:  1984        PMID: 6720271     DOI: 10.1111/j.1755-3768.1984.tb06769.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  5 in total

1.  Argon laser trabeculoplasty controls one third of patients with progressive, uncontrolled open-angle glaucoma for five years.

Authors:  K A Baez; G L Spaeth
Journal:  Trans Am Ophthalmol Soc       Date:  1991

2.  Role of argon laser trabeculoplasty as primary and secondary therapy in open angle glaucoma in Indian patients.

Authors:  H C Agarwal; R Sihota; C Das; T Dada
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

3.  A review of surgical alternatives to medical therapy for glaucoma.

Authors:  D E Gaasterland
Journal:  J Natl Med Assoc       Date:  1988-07       Impact factor: 1.798

4.  Long-term efficacy of primary laser trabeculoplasty.

Authors:  T Elsås; H Johnsen
Journal:  Br J Ophthalmol       Date:  1991-01       Impact factor: 4.638

Review 5.  Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma: A Review of the Literature with Updates on Surgical Management.

Authors:  Pasquale Plateroti; Andrea Maria Plateroti; Solmaz Abdolrahimzadeh; Gianluca Scuderi
Journal:  J Ophthalmol       Date:  2015-10-29       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.